Effect of Silencing Neutrophil Gelatinase-Associated Lipocalin in Ovarian Cancer Cells on Epithelio-Mesenchymal Transition
- *Corresponding Author:
- Dr. Ratana Lim
Department of Obstetrics and Gynaecology
University of Melbourne , Mercy Hospital for Women
Level 4/163 Studley Road, Heidelberg, Victoria
Tel: 61-3-8458 4363
Fax: 61-3-8458 4380
Email: [email protected]
Received Date: July 22, 2011; Accepted Date: August 22, 2011; Published Date: August 26, 2011
Citation: Lim R, Lappas M, Ahmed N, Borregaard N, Quinn MA, et al. (2011) Effect of Silencing Neutrophil Gelatinase-Associated Lipocalin in Ovarian Cancer Cells on Epithelio-Mesenchymal Transition. J Mol Biomark Diagn 2:114 doi:10.4172/2155-9929.1000114
Copyright: © 2011 Lim R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Objectives: Previously, we reported that neutrophil gelatinase-associated lipocalin (NGAL) is present in epithelial ovarian cancer cells, but not mesenchymal cancer cells. Furthermore, we reported that epithelial growth factor (EGF) induced epithelio-mesenchymal transition (EMT) in epithelial ovarian cancer cells and concomitantly suppressed NGAL expression. We hypothesised that inhibition of NGAL expression induces EMT in these cells.
Methods: NGAL knockdown was achieved using siRNA in ovarian cancer cell line OVCA 429. NGAL siRNAtreated cells [n=3] were assayed for EMT markers such as migration and invasion assays, and E-cadherin, N-cadherin, Snail, ?-catenin and vimentin expression by Western blot.
Results: There were no significant differences between NGAL siRNA-treated cells and controls for the protein markers. There was an increase in cell migration for NGAL siRNA-treated cells compared to control (96 h post transfection), however there was no change in cell invasiveness between treatments.
Conclusions: We conclude that direct NGAL inhibition by siRNA does not induce a mesenchymal transition of ovarian cancer cells.